- Home
- SHOT vs ANTX Comparison
SHOT vs ANTX Comparison
Compare SHOT & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOT
- ANTX
- Stock Information
- Founded
- SHOT 2018
- ANTX 2017
- Country
- SHOT United States
- ANTX United States
- Employees
- SHOT N/A
- ANTX N/A
- Industry
- SHOT Biotechnology: Pharmaceutical Preparations
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- SHOT Health Care
- ANTX Health Care
- Exchange
- SHOT Nasdaq
- ANTX Nasdaq
- Market Cap
- SHOT 33.4M
- ANTX 38.5M
- IPO Year
- SHOT 2020
- ANTX 2022
- Fundamental
- Price
- SHOT $0.51
- ANTX $1.25
- Analyst Decision
- SHOT
- ANTX Buy
- Analyst Count
- SHOT 0
- ANTX 4
- Target Price
- SHOT N/A
- ANTX $3.50
- AVG Volume (30 Days)
- SHOT 1.1M
- ANTX 54.4K
- Earning Date
- SHOT 05-14-2025
- ANTX 05-13-2025
- Dividend Yield
- SHOT N/A
- ANTX N/A
- EPS Growth
- SHOT N/A
- ANTX N/A
- EPS
- SHOT N/A
- ANTX N/A
- Revenue
- SHOT $701,967.00
- ANTX N/A
- Revenue This Year
- SHOT N/A
- ANTX N/A
- Revenue Next Year
- SHOT N/A
- ANTX N/A
- P/E Ratio
- SHOT N/A
- ANTX N/A
- Revenue Growth
- SHOT 246.36
- ANTX N/A
- 52 Week Low
- SHOT $0.34
- ANTX $0.87
- 52 Week High
- SHOT $1.77
- ANTX $3.07
- Technical
- Relative Strength Index (RSI)
- SHOT 58.92
- ANTX 44.74
- Support Level
- SHOT $0.37
- ANTX $1.18
- Resistance Level
- SHOT $0.46
- ANTX $1.33
- Average True Range (ATR)
- SHOT 0.06
- ANTX 0.08
- MACD
- SHOT 0.00
- ANTX -0.00
- Stochastic Oscillator
- SHOT 87.36
- ANTX 57.89
About SHOT Safety Shot Inc.
Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.